ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
45 announcements
Dr. Reddy's Laboratories launched its generic Semaglutide Injection in Canada following Health Canada approval. This marks the first generic Semaglutide authorization in a G7 country.
Dr. Reddy's Board approved the re-appointment of Dr. K P Krishnan and appointed Mr. Srikanth Velamakanni as Independent Directors. These appointments strengthen corporate governance and leadership.
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹7,546 Cr (-11.5% YoY) and net profit of ₹221.3 Cr (-86.1% YoY) for Q4 FY26.
Dr. Reddy's Laboratories reported FY26 consolidated revenue of ₹33,593.3 Crore and recommended a ₹8 dividend per share. Performance reflects lower generic sales and one-time impact costs.
Dr. Reddy's Laboratories granted 11,92,234 stock options at Rs. 1,293.90 per share, totaling approximately ₹154.21 Crore. Options vest over three years to incentivize employees.
Dr. Reddy's Laboratories received a Notice of Compliance from Health Canada for its generic Semaglutide Injection. This approval authorizes the company to commercialize and distribute the product in Canada, marking a significant milestone in its GLP-1 therapy portfolio. Launch preparations for 2 mg and 4 mg pens are currently underway.
Dr. Reddy's Laboratories clarified that recent trading volume increases are not driven by undisclosed material events. The company separately confirmed it received Drug Identification Numbers from Health Canada for its Semaglutide Injection on April 22, 2026, though final 'Notice of Compliance' approval is still pending.
Dr. Reddy's clarified a news report regarding its Semaglutide Injection. The company confirmed it is awaiting 'Notice of Compliance' from Health Canada but has received 'Drug Identification Numbers' as of April 22, 2026. Management stated there is no material impact on the company from the news article.
Dr. Reddy's Laboratories clarified a news report regarding its Semaglutide Injection. The company confirmed it has not yet received a 'Notice of Compliance' from Health Canada but did receive 'Drug Identification Numbers' (DINs) on April 22, 2026. The company continues to engage with regulatory authorities for Canadian market approval.
Dr. Reddy's Laboratories clarified news reports regarding its Semaglutide Injection. The company confirmed it is still awaiting 'Notice of Compliance' from Health Canada, though it received Drug Identification Numbers on April 22, 2026. Management remains engaged with regulatory authorities to bring the product to the Canadian market.
Dr. Reddy's Laboratories Limited has scheduled a board meeting on May 12, 2026, to consider a final dividend. The trading window for designated persons is closed from March 25, 2026, until May 14, 2026.
Dr. Reddy's Laboratories Ltd has scheduled a Board of Directors meeting to consider recommending a final dividend for the financial year 2025-26. This follows a prior intimation dated March 23, 2026.
Dr. Reddy's Laboratories' Russian subsidiary received a final penalty of ₹1.14 Crore (RUB 9.27 million) from the Russian Tax Authority. The penalty relates to VAT re-classification of marketing services. The company stated this fine has no material impact on its financials or operations.
Dr. Reddy's Laboratories Ltd reported net profit of ₹1,190 Cr (-15.2% YoY) for Q3 FY26.
Dr. Reddy's Laboratories Ltd has entered into an agreement to sell its 100% stake in subsidiary Svaas Wellness Limited for ₹2.23 Crore. The buyer, Enspirit Technology Services Private Limited, is not a related party. The divestment is part of a strategic realignment, as the unit contributed only 0.09% to consolidated turnover.